Comment
doi: 10.1016/S2468-1253(23)00073-0.
Treatment de-escalation in Crohn's disease
Affiliations
- PMID: 37030299
- DOI: 10.1016/S2468-1253(23)00073-0
Item in Clipboard
Comment
Treatment de-escalation in Crohn's disease
Lancet Gastroenterol Hepatol.
2023 May.
No abstract available
Conflict of interest statement
CM receives educational travel bursaries from Ferring, Janssen, and Dr Falk Pharma. DK receives educational travel bursaries from Dr Falk Pharma and participates in advisory boards for AbbVie, Takeda, Galapagos, Janssen, and Pfizer.
Comment in
-
Treatment de-escalation in Crohn's disease - Author's reply.Lancet Gastroenterol Hepatol. 2023 May;8(5):401-402. doi: 10.1016/S2468-1253(23)00081-X. Lancet Gastroenterol Hepatol. 2023. PMID: 37030300 No abstract available.
Comment on
-
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
